Publicaties

 

Hieronder treft u aantal nieuwe publicaties, abstracts of presentaties aan waar naar de betreffende studie is verwezen. 

Een lijst van alle publicaties tot en met december 2018 vindt u hier.

 

AMAROS

10-year follow-up of AMAROS shows benefits for post-operative radiotherapy to the axilla in patients with a tumour-positive sentinel node

EJT Rutgers et al, SABCS 2018 oral presentation

 

HERA

- Association of p27 and Cyclin D1 Expression and Benefit from Adjuvant Trastuzumab Treatment in HER2-Positive Early Breast Cancer: A TransHERA Study         

Filipits M, Dafni U, Gnant M, Polydoropoulou V, Hills M, Kiermaier A, de Azambuja E, Larsimont D, Rojo F, Viale G, Toi M, Harbeck N, Prichard KI, Gelber RD, Dinh P, Zardavas D, Leyland-Jones B, Piccart-Gebhart MJ, Dowsett M; TransHERA investigators    

Clin Cancer Res. 2018 Jul 1;24(13):3079-3086.

 

CALOR

- The Final Verdict: Chemotherapy Benefits Estrogen Receptor-Negative Isolated Local Recurrence.

Chan N et al, J Clin Oncol. 2018 Apr 10, doi: 10.1200/JCO.2017.77.4877.

- Efficacy of Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional Recurrence of Breast Cancer: Final Analysis of the CALOR Trial;

Wapnir IL, et al, J Clin Oncol. 2018 Feb 14 doi: 10.1200/JCO.2017.76.5719.

 

MATADOR

- Tumor infiltrating lymphocytes predict benefit from TAC but not from ddAC in triple negative breast cancer in the randomized MATADOR trial (BOOG 2004-04) ; A.G.J. van Rossum et al, ESMO 2018 Abstract 189 PD

 

DATA

- No impact of osteoporosis or bisphosphonate use for osteoporosis on breast cancer outcome: A sub-study of the DATA trial; I.E. van Hellmond et al, SABCS 2018 abstract P4-14-11

 

ALLTO

- Pregnancies during and following trastuzumab (T) and/or lapatinib (L) in patients (pts) with HER2-positive (HER2+) early breast cancer (EBC): Analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trials

Lambertini M, et al, Journal of Clinical Oncology 36, no. 15_suppl (May 20 2018) 10065-10065

- Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients 

Lambertini M, et al, J Natl Cancer Inst. 2018 Jun 5. doi: 10.1093/jnci/djy094

- Characterisation of the HLA-DRB1*07:01 biomarker for lapatinib-induced liver toxicity during treatment of early-stage breast cancer patients with lapatinib in combination with trastuzumab and/or taxanes    

C F. Spraggs, et al, Pharmacogenomics J. 2018 May 22;18(3):480-486

- Impact of body mass index (BMI) and weight change after treatment in patients (pts) with HER2-positive (HER2+) early breast cancer (EBC): Secondary analysis of the ALTTO BIG 2-06 trial

Martel S, et al, Journal of Clinical Oncology 36, no. 15_suppl (May 20 2018) 10067-10067

 

Male Breast cancer

- Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program.

Cardoso et l, Ann Oncol. 2018 Feb 1;29(2):405-417. doi: 10.1093/annonc/mdx651.

 

MONALEESA-2

  • Sonke GS, et al. Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial. Breast Cancer Res Treat 2018;167(3):659-69.
  • Hortobagyi GN, et al. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann Oncol 2018;29(7):1541-7.
  • O'Shaughnessy J, et al. Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2- advanced breast cancer in the randomized MONALEESA-2 trial. Breast Cancer Res Treat 2018;168(1):127-34.

 

MONALEESA-3

  • Slamon DJ, et al. Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J Clin Oncol 2018;36(24):2465-72.

 

D-Care

  • Coleman R. et al. Presented at: American Society of Clinical Oncology, June 1-5, 2018; Chicago, IL. USA.

 

Monarch-3

  • Goetz MP, et al. Presented at: American Society of Clinical Oncology, June 1-5, 2018; Chicago, IL. USA.

 

Pernetta

  • Huober J, et al. Presented at: European Society for Medical Oncology (ESMO) Congress, Munich, Germany, October 19-23, 2018.

 

Male BC

  • Cardoso F et al. Characterization of Male BC: results of the EORTC 10085/TBCRC/BIG/NABCG International Male BC Cancer Program. Ann Oncol 2018;29(2).

 

NEO-ZOTAC

  • (Ingediend ter publicatie) De Groot F, et al. Strong CD8+ lymphocyte infiltration in combination with expression of HLA class I is 1 associated with better tumor control in breast cancer patients treated with neoadjuvant 2 chemotherapy with or without zoledronic acid.

 

STOP & GO

  • Claessens AK, et al. Intermittent versus continuous first-line treatment for HER2-negative metastatic breast cancer: the Stop & Go study of the Dutch Breast Cancer Research Group (BOOG). Breast Cancer Res Treat 2018 Aug 18.

 

SUPREMO

- Quality of life after postmastectomy radiotherapy in patients with intermediate-risk breast cancer (SUPREMO): 2-year follow-up results of a randomised controlled trial

G.Velikova, L.J. Williams, S.Willis, J.M. Dixon, J. Loncaster, M. Hatton, et al

Lancet Oncology, V 19, issue 11, p1516-1529, November 01, 2018

Young Boost

  • Brouwers PJ, et al. Predictors for poor cosmetic outcome in patients with early stage breast cancer treated with breast conserving therapy: results of the Young boost trial. Radiother Oncol 2018;128(3):434-41.

 

TRAIN-2

  • Van Ramshorst MS, et al; Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicenter, open-label, randomized, phase 3 trial. Lancet Oncol 2018; 19: 1543-1698

 

DIRECT

  • DIetary REstriction as an adjunct to neoadjuvant ChemoTherapy for HER2-negative breast cancer: Final results from the DIRECT trial (BOOG 2013-04).S. de Groot et al, SABCS Poster presentation(P1-15-20)

 

TRAIN-3

  • van der Voort A et al Image-guided de-escalation of neoadjuvant chemotherapy in HER2-positive breast cancer:  the TRAIN-3 study. SABCS 2018 poster presentation abstract number 1079

 

SONIA

  • Selecting the optimal position of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer - the SONIA study: study protocol for a randomized controlled trial. BMC Cancer. 2018 Nov 20;18(1):1146. doi: 10.1186/s12885-018-4978-1.

    van Ommen-Nijhof A1, Konings IR2, van Zeijl CJJ2, Uyl-de Groot CA3, van der Noort V1, Jager A4, Sonke GS5; SONIA study steering committee.